Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
about
Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.Research progress of neuroblastoma related gene variations.A single center clinical analysis of children with high-risk neuroblastoma.SPARC overexpression suppresses radiation-induced HSP27 and induces the collapse of mitochondrial Δψ in neuroblastoma cellsEfficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.Angelica polymorpha Maxim Induces Apoptosis of Human SH-SY5Y Neuroblastoma Cells by Regulating an Intrinsic Caspase Pathway.Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients.SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR‑410 in human neuroblastoma cells.Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients.Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.Genetic discoveries and treatment advances in neuroblastoma.Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment.Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation.The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.Dinutuximab: A Review in High-Risk Neuroblastoma.Action of HMGB1 on miR-221/222 cluster in neuroblastoma cell lines.Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.Management of Neuroblastoma: ICMR Consensus Document.Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort.RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue.Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum.Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.MRI-guided radiotherapy of the SK-N-SH neuroblastoma xenograft model using a small animal radiation research platform.Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastomaCD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model.Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.Sensitization of neuroblastoma for vincristine-induced apoptosis by Smac mimetic LCL161 is attended by G2 cell cycle arrest but is independent of NFκB, RIP1 and TNF-α.Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.
P2860
Q30239861-40BDDCF8-B952-4E66-9A68-B9CD649DFBE9Q33442162-9DC761B1-ED27-4CC0-A1EC-FC38EDEC90E2Q33566987-B6D035E6-7C55-4D57-A54B-7837E96AA2C7Q33728327-231AECB3-E51C-4A73-AC2F-308ADF284FC4Q33751169-6B573C32-A79B-4708-A076-23B225C4F42FQ36157777-C9A522DD-8BEC-480D-9363-66A52865A959Q36159646-922BF9AF-D5A4-4D09-840C-3C2BEDF3954BQ36353230-EBD4B863-F6CE-4096-BFF6-9BF420B88E34Q36591288-B45DC90A-0229-46A6-85E0-B52135332DBFQ37215353-F2221A3C-B3DA-42EA-9D39-C6C4CA7419BDQ37252700-3BB92F80-209F-4978-9C2D-2AF194FAD230Q37529593-1574B0AC-CA88-4B48-8000-B99FFB7DA9A5Q37686989-FF25D8B1-C419-4A89-A05E-77032840FF0DQ37706191-B689C3B7-6021-4F45-95BB-E223B51BE8DEQ38635452-CA550190-3C0A-4D43-8316-DED83E894813Q38635551-3BF2E6AE-EA90-40AB-A705-45D4C4F11B3CQ38697403-6932FF01-5A15-4A32-8D82-2B512E70F299Q38705079-08646C80-E31F-4444-8E85-3939A9F4AAB9Q38705578-DC880633-A235-4E3F-A13A-FEF3EE9742C2Q38739672-A8FDFB28-C991-49D8-BA81-25D0DB84CDC1Q38747810-7BCF9E79-C5AB-44DE-B514-DD75D3A8F1DBQ38751090-13314CCC-71F2-4E6E-886B-678BB85A5589Q38804821-F598B8C5-E4EE-4A48-AF57-584F75165FB4Q39052883-81BBD1A2-11D8-4ADF-BB72-84A4C67BA890Q39214599-D0711CE8-7F1C-4169-BCA9-CED5BA2F9B7EQ39459548-C60CE671-D7DF-45F4-9439-F2D6C02981EEQ40553571-6621F7BA-BE16-47BC-9C74-F16E6802B799Q40651848-8B997D44-8E2F-467D-AF04-7E09616DAC50Q40979034-2E8F4297-4A55-4335-AE39-B0D06B40AEB8Q41581177-7EC3F095-7284-4559-88CD-05C2E1260CADQ41592643-D90A0F5F-AC09-460A-8FF1-73B40528F77DQ41698485-4A07E869-7C67-4E76-AFF0-DE1CEA887A31Q41840140-24C4790C-62D8-47E2-AD01-22968404E617Q42282780-66121FC8-856A-4688-B96A-F1E843F75C58Q42333778-C9578DAF-1EB3-4318-B2AC-71BE89BFCF05Q42371465-48278DA4-C601-492F-8E80-7A9094F5D275Q42697385-6F87E09A-258D-4782-A443-6859A9C90CECQ46644093-E1D5536D-64EF-45F1-A4FD-9D612FFBDC17Q47107025-D1C15966-84B0-41BA-BFE9-330C56BB6694Q47123875-B7A2D7CD-A2E1-45BF-8FA7-1318523855C1
P2860
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
@ast
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
@en
type
label
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
@ast
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
@en
prefLabel
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
@ast
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
@en
P2093
P2860
P50
P356
P1476
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
@en
P2093
Akira Nakagawara
Andrew D J Pearson
Frank Berthold
Gudrun Schleiermacher
Julie R Park
Katherine K Matthay
Mark A Applebaum
Navin R Pinto
Samuel L Volchenboum
Wendy B London
P2860
P304
P356
10.1200/JCO.2014.59.4648
P407
P577
2015-08-24T00:00:00Z